Initial preliminary results from the Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of accelerating second doses as the Delta variant continues to spread, particularly with the vast majority of Canadians having received only a single vaccine dose. This is the first pan-Canadian study using samples from a wide range of participants to confirm evidence from vaccine manufacturers’ clinical trials, as well as findings in a recent preprint from the United Kingdom and other smaller studies.   Participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations contributed to the COVID-19 Antibody Study. https://bit.ly/3gVLeb2  

Atlantic PATH is thrilled to be involved in the newly funded project led by Dr. Juliet Daniel at McMaster University. The New Frontiers in Research Fund 2020 Exploration grants target high-risk, high-reward and interdisciplinary research. This work will focus on disparities in cancer incidence and outcomes in a Black Nova Scotian community (Shelburne, Nova Scotia). This research is truly interdisciplinary, incorporating natural and social sciences to consider the role of environmental, biological, genetic, socioeconomic, and lifestyle factors with the high cancer incidence and mortality in this community. We’re pleased to be working with our Dalhousie University colleagues, Dr. Ingrid Waldron (School of Nursing), Dr. Jong Sung Kim (Faculty of Medicine), Dr. Paola Marignani (Faculty of Medicine) and Dr. Charles Hostovsky (School of Planning).   https://bit.ly/3fHw3CU